Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Twelve outstanding articles have been shortlisted for this year’s Max Perutz Science Writing Award, the MRC’s annual writing competition. The shortlist includes our DPhil student Magda Mareckova (pictured).

Good luck to our DPhil student Magda Mareckova. Her article: “One in ten women suffers from endometriosis - can studying the endometrium cell by cell help us diagnose it?” is shortlisted for this year’s Max Perutz Science Writing Award, the MRC’s annual writing competition.

Latest news

Oxford to lead Europe's largest miscarriage research centre in partnership with Tommy's

The Nuffield Department of Women's & Reproductive Health is proud to announce that it is now leading Tommy's National Centre for Miscarriage Research, alongside existing partners: the University of Birmingham, the University of Warwick, and Imperial College London.

Ovarian Cancer Awareness Day 2026 highlights the need for earlier detection and better outcomes

Today, on World Ovarian Cancer Day, we recognise the impact ovarian cancer has on women and families worldwide, and the urgent need for earlier diagnosis, improved treatment, and better survival outcomes. The day also highlights the importance of continued research to improve understanding of ovarian cancer biology, diagnosis, treatment, and patient outcomes. High-grade serous ovarian cancer is the most common subtype of ovarian cancer, with many patients diagnosed at an advanced stage. Survival outcomes remain closely linked to the stage at which the disease is diagnosed.

Phase 2 Endometriosis Study Highlights a Novel Molecular Imaging Agent as a Promising Diagnostic and Monitoring Tool

A Phase II Study, published in The Lancet Obstetrics, Gynaecology & Women's Health, highlights the potential of a new molecular imaging agent, ‘99mTc-maraciclatide’, when used alongside a non-invasive scan to diagnose and monitor the development and treatment of Endometriosis.

Our Research Groups